City Therapeutics Secures $135M to Advance RNAi Medicines with John Maraganore

City Therapeutics has successfully raised $135 million in a Series A financing round, spearheaded by Arch Venture Partners with contributions from Fidelity Management & Research and Regeneron Ventures[1][2]. This funding will fuel the company's initiatives to develop advanced RNA interference (RNAi) medicines, particularly focusing on creating smaller, potent RNAi triggers known as "cleavage-inducing tiny RNAs"[2]. Co-founded by John Maraganore, former CEO of Alnylam Pharmaceuticals, City Therapeutics is set to begin its first clinical program by the end of next year, with the goal of launching one to two investigational new drug applications each year from 2026[1].